Effect of Exenatide in Obese Patients With Accelerated Gastric Emptying

NCT02160990 on ClinicalTrials.gov · last registry update 2016-08-09

A small phase 4 — 20 participants, against a typical 75. The sponsor logged completion for March 2015. Primary outcome, as filed: Gastric Emptying Half-time (T 1/2) of Solids. exenatide is approved in the US, but not for obesity — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P4
Drug: exenatide
Bydureon, Byetta
Sponsor: Mayo Clinic
Sponsor type: Other
Enrollment: 20
Started: 2014-06
Primary completion: 2015-03 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Gastric Emptying Half-time (T 1/2) of Solids

Conditions studied

Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.